Advertisement
Home Tags Herpes Zoster (Shingles)

Tag: Herpes Zoster (Shingles)

Concurrent Zoster, Flu Vaccines Tied to Lower Subsequent Flu Vaccine Uptake

0

Patients may misattribute adverse effects commonly caused by the zoster vaccine to the influenza vaccine

Live Attenuated Zoster Vaccine Safe for Patients Receiving TNF Inhibitors

0

No cases of varicella infection found; cumulative incidence of varicella infection or shingles was 0 percent

From 2008 to 2018

2008 to 2018 Saw Increase in Shingles Vaccination in Over 60s

0
Women equally as likely as men to have received vaccine; coverage highest for non-poor, those with higher education
Vaccination with zoster vaccine live is associated with a reduced risk for stroke among older adults

ASA: Herpes Zoster Vaccine May Reduce Risk for Stroke

0
Risk significantly reduced for stroke events, acute ischemic strokes, hemorrhagic strokes in older adults
The relative incidence of shingles is lower in adults after exposure to a household contact with chickenpox

Adult Exposure to Chickenpox Cuts Shingles Risk

0
A modest but long-lasting protective effect was observed, but full protection not achieved
A two-dose course of recombinant zoster vaccine is associated with a reduction in the incidence of herpes zoster among adults who have undergone autologous hematopoietic stem cell transplantation

Two-Dose Course of Vaccine After HSCT Cuts Incidence of Zoster

0
Incidence of herpes zoster decreased during median 21-month follow-up after autologous HSCT
From 2003 to 2014

2003 to 2014 Saw Incidence of Herpes Zoster Drop in Children

0
Vaccinated children had 78 percent lower rate of HZ incidence than unvaccinated children
From 2004 to 2012

Herpes Zoster Ophthalmicus Cases Increased in 2004 to 2012

0
Highest rates of HZO seen in older adults, women, and in whites versus other racial groups
Vaccination with recombinant zoster vaccine seems cost-effective under a wide range of conditions

Recombinant Zoster Vaccine Cost-Effective in Simulation

0
Incremental cost-effectiveness ratio varied from $10,000 to $47,000 per QALY for RZV versus no vaccine
During the first eight months of recombinant zoster vaccine (RZV) use

CDC Examines Safety of Recombinant Zoster Vaccine

0
Total of 4,381 reports of adverse events during first eight months of use; 3 percent were serious